Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18735945 | 0.80 | MGLL (0.38) | MAPTLMNASIGMAR1ALDH1A1TSHR | |
| SCHEMBL24079207 | 0.78 | CHRM5 (0.44) | MEN1KMT2ACHRM5CHRM3LMNA | |
| SCHEMBL872595 | 0.78 | USP2 (0.46) | MAPTLMNAALDH1A1ANPEPTSHR | |
| SCHEMBL19841252 | 0.75 | ALDH1A1 (0.41) | MEN1KMT2AMAPTCARM1PRMT6 | |
| SCHEMBL21919497 | 0.73 | CHRM5 (0.39) | CHRM5SIGMAR1ALDH1A1 | |
| SCHEMBL14381568 | 0.73 | ALDH1A1 (0.44) | MEN1KMT2AMAPTCARM1PRMT6 | |
| SCHEMBL24631645 | 0.73 | ALDH1A1 (0.44) | MEN1KMT2AMAPTCARM1PRMT6 | |
| SCHEMBL18470674 | 0.70 | HRH3 (0.50) | MEN1KMT2AMAPTCARM1PRMT6 | |
| SCHEMBL24407875 | 0.70 | — | — | |
| SCHEMBL25056697 | 0.70 | MEN1 (0.41) | MEN1KMT2AMAPTATMCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4806746-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| EP-1590360-A4 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | IND RES LTD (NZ) | 2009-06-24 | — | — | EP | claimed |
| EP-1881984-A1 | INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, a division of YESHIVA UNIVERSITY (US) | 2008-01-30 | — | — | EP | claimed |
| WO-2006123953-A1 | INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2006-11-23 | — | — | WO | claimed |
| EP-1590360-A1 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2005-11-02 | — | — | EP | claimed |
| WO-2004069856-A1 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2004-08-19 | — | — | WO | claimed |
| EP-4219516-A2 | CHIRAL CONTROL | Wave Life Sciences Ltd. (SG) | 2023-08-02 | — | — | EP | disclosed |
| US-11634710-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-04-25 | — | — | US | disclosed |
| US-20220401467-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-12-22 | — | — | US | disclosed |
| US-11013757-B2 | Oligonucleotides, compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2021-05-25 | — | — | US | disclosed |
| US-20200299692-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | US | disclosed |
| US-20190209604-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-07-11 | — | — | US | disclosed |
| WO-2018067973-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-04-12 | — | — | WO | disclosed |
| WO-2017192664-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017062862-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-04-13 | — | — | WO | disclosed |
| EP-1590360-A4 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | IND RES LTD (NZ) | 2009-06-24 | — | — | EP | disclosed |
| EP-1881984-A1 | INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, a division of YESHIVA UNIVERSITY (US) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006123953-A1 | INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-1590360-A1 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004069856-A1 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299692-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | MEN1 3713/4885KMT2A 1986/4885MAPT 1951/4885 |
| US-20190209604-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | TLR9, RNGTT, NT5C3B | MEN1 4562/4885KMT2A 1618/4885MAPT 4749/4885 |
| US-20220401467-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | TLR9, RNGTT, NT5C3B | MEN1 4562/4885KMT2A 1618/4885MAPT 4749/4885 |
| US-11013757-B2 | Oligonucleotides, compositions and methods thereof | TLR9, RNGTT, NT5C3B | MEN1 4562/4885KMT2A 1618/4885MAPT 4749/4885 |
| US-11634710-B2 | Oligonucleotide compositions and methods thereof | RBM17, HNRNPA2B1, HNRNPA1 | MEN1 3713/4885KMT2A 1986/4885MAPT 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.